Literature DB >> 22386193

Concordance of tumor differentiation among brothers with prostate cancer.

K Fredrik Jansson1, Olof Akre, Hans Garmo, Anna Bill-Axelson, Jan Adolfsson, Pär Stattin, Ola Bratt.   

Abstract

BACKGROUND: Genetic factors seem to be of greater importance in prostate cancer than in other forms of cancer. Studies have suggested familial concordance in survival, but the extent to which that is due to tumor characteristics is not known.
OBJECTIVE: We hypothesized that a brother of an index case with prostate cancer is at particularly increased risk of prostate cancer with the same tumor differentiation as the index case. DESIGN, SETTING AND PARTICIPANTS: We identified 21,930 brothers of index cases with prostate cancer in the Prostate Cancer Data Base Sweden and followed them up for incidence of prostate cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The relative risk of Gleason score-specific prostate cancer in the cohort of brothers was estimated by using the standardized incidence ratio (SIR) stratified by Gleason score of the index case. We estimated 95% confidence intervals (CIs) assuming a Poisson distribution. RESULTS AND LIMITATIONS: Among brothers of index cases with Gleason score 8-10 cancer, the SIR was 2.53 (95% CI, 1.97-3.21) for a Gleason score 2-6 cancer and 4.00 (95% CI, 2.63-5.82) for a Gleason score 8-10 cancer. SIR for Gleason score 2-6 cancer among brothers decreased with time since the date of the index cases' diagnoses, whereas the risk of Gleason 8-10 cancer increased over time for brothers of index cases with Gleason 8-10 cancer (p for trend = 0.009).
CONCLUSIONS: Brothers of men with high-grade prostate cancer are at particularly increased risk of high-grade prostate cancer. Likewise, there is a concordance of less malignant prostate cancers within families. These findings may have direct clinical relevance for counseling men with a family history of prostate cancer.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386193     DOI: 10.1016/j.eururo.2012.02.032

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland.

Authors:  F O'Kelly; S Elamin; A Cahill; P Aherne; J White; J Buckley; K N O'Regan; A Brady; D G Power; M F O'Brien; P Sweeney; N Mayer; P J Kelly
Journal:  World J Urol       Date:  2013-10-16       Impact factor: 4.226

2.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

3.  Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.

Authors:  Daniel C Koboldt; Krishna L Kanchi; Bin Gui; David E Larson; Robert S Fulton; William B Isaacs; Aldi Kraja; Ingrid B Borecki; Li Jia; Richard K Wilson; Elaine R Mardis; Adam S Kibel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-02       Impact factor: 4.254

4.  Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study.

Authors:  Raffaele Baio; Giorgio Napodano; Christian Caruana; Giovanni Molisso; Umberto Di Mauro; Olivier Intilla; Umberto Pane; Costantino D'Angelo; Antonella Bianca Francavilla; Claudio Guarnaccia; Francesca Pentimalli; Roberto Sanseverino
Journal:  Mol Clin Oncol       Date:  2022-06-20

5.  Survival outcomes in men with a positive family history of prostate cancer: a registry based study.

Authors:  Mann Ang; Martin Borg; Michael E O'Callaghan
Journal:  BMC Cancer       Date:  2020-09-18       Impact factor: 4.430

Review 6.  The Genetic Complexity of Prostate Cancer.

Authors:  Eva Compérat; Gabriel Wasinger; André Oszwald; Renate Kain; Geraldine Cancel-Tassin; Olivier Cussenot
Journal:  Genes (Basel)       Date:  2020-11-25       Impact factor: 4.096

7.  Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.

Authors:  Luigi A M J G van Riel; Auke Jager; Dennie Meijer; Arnoud W Postema; Ruth S Smit; André N Vis; Theo M de Reijke; Harrie P Beerlage; Jorg R Oddens
Journal:  Ther Adv Urol       Date:  2022-03-26

8.  Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.

Authors:  Burcu F Darst; Tokhir Dadaev; Ed Saunders; Xin Sheng; Peggy Wan; Loreall Pooler; Lucy Y Xia; Stephen Chanock; Sonja I Berndt; Susan M Gapstur; Victoria Stevens; Demetrius Albanes; Stephanie J Weinstein; Vincent Gnanapragasam; Graham G Giles; Tu Nguyen-Dumont; Roger L Milne; Mark Pomerantz; Julie A Schmidt; Lorelei Mucci; William J Catalona; Kurt N Hetrick; Kimberly F Doheny; Robert J MacInnis; Melissa C Southey; Rosalind A Eeles; Fredrik Wiklund; Zsofia Kote-Jarai; David V Conti; Christopher A Haiman
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

9.  Glyoxalase 1-419C>A variant is associated with oxidative stress: implications in prostate cancer progression.

Authors:  Cinzia Antognelli; Letizia Mezzasoma; Ettore Mearini; Vincenzo Nicola Talesa
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

10.  Identification of core genes associated with prostate cancer progression and outcome via bioinformatics analysis in multiple databases.

Authors:  Yutao Wang; Jianfeng Wang; Kexin Yan; Jiaxing Lin; Zhenhua Zheng; Jianbin Bi
Journal:  PeerJ       Date:  2020-03-31       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.